Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:09:17.405Z.
Consensus retrieved: 2026-10-06T15:32:24.533Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:09:17.405Z.
Quote observation: 2026-10-06T17:55:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ff2bb50ee92c82d9bafac158d2b6876f5ec2ee6c7e034d44b6b8dcedc71e7a96
Forward PE Ratio (N/A) = Dated Quote Price ($1.44) / Consensus Forward EPS ($-2.24)
FORWARD PE RATIO
N/A
Pulmatrix, Inc.
Market Cap
$5.26M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Pulmatrix, Inc. (PULM) | $5.26M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.34M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.04M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.52M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.44, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.24 | $-2.24 – $-2.24 | 1 | n/m |
| 2027-12-31 | $0.58 | $0.58 – $0.58 | 1 | 2.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
